8-K: Waters Corp. Supplements Merger Proxy Amid Shareholder Lawsuits

Waters Corporation has filed supplemental disclosures to its proxy statement/prospectus for the upcoming merger with BD's Biosciences and Diagnostic Solutions business, addressing shareholder litigation and demand letters.

Summary

• Waters Corporation is proceeding with a Reverse Morris Trust transaction involving Becton, Dickinson and Company (BD) and its SpinCo subsidiary (BD's Biosciences and Diagnostic Solutions business).
• The transaction involves BD distributing SpinCo shares to its stockholders, followed by a merger where SpinCo becomes a wholly-owned subsidiary of Waters.
• A special meeting of Waters stockholders is scheduled for January 27, 2026, to vote on matters necessary for the merger.
• Two lawsuits and several demand letters have been filed by purported Waters stockholders, alleging the preliminary proxy statement/prospectus omitted material information.
• Waters believes its disclosures comply with law but is voluntarily providing supplemental disclosures to moot claims and minimize delay risks, without admitting wrongdoing.
• The supplemental disclosures amend and restate sections concerning the Background of the Merger, including details about M&A evaluation, the March 2025 proposal, confidentiality agreement terms, and pre-merger discussions.
• New prospective financial information tables are added for Waters Standalone Baseline, Waters Standalone Advocacy Case, and Waters Management Adjusted SpinCo Financial Projections for fiscal years 2025E-2034E.
• Discounted Cash Flow Analysis details for Waters and the BDS Business are updated, including discount rates (9.0% to 10.0%) and terminal exit multiples (16.0x to 18.0x).
• Selected Comparable Company Analysis tables for Waters and BDS Business are amended with updated EV/Adj. EBITDA multiples for 2025E and 2026E.
• Selected Precedent Transactions Analysis tables for Waters and BDS Business are supplemented with additional transaction details including approximate LTM Multiples.
• Waters Broker Target Prices Analysis is updated, showing a per share price target range of $350.00 to $460.00, with a median of approximately $375.00.

Sentiment

Score: 6

Explanation: The filing presents a strategically sound merger with anticipated synergies, supported by the board. However, the presence of shareholder lawsuits alleging disclosure deficiencies and the need for supplemental disclosures introduce a notable element of uncertainty and potential for delays or increased costs. While management is proactively addressing these issues, the litigation itself is a negative factor that tempers overall sentiment.

Positives

• The Waters Board unanimously recommends voting FOR the merger proposals, indicating strong internal support for the transaction.
• The merger is structured as a tax-efficient Reverse Morris Trust transaction, which can be beneficial for shareholders.
• Anticipated strong revenue and cost synergy opportunities from the combination, including cross-selling Waters products into research markets, promoting LC-MS in clinical diagnostics, and optimizing logistics and procurement.
• Waters is taking proactive steps by providing supplemental disclosures to address shareholder litigation and minimize potential merger delay risks, demonstrating a commitment to completing the transaction.

Negatives

• Two lawsuits have been filed by purported Waters stockholders alleging that the Proxy Statement/Prospectus omitted material information, rendering it incomplete and misleading.
• Waters has received demand letters from purported stockholders making similar allegations, indicating broader shareholder concerns.
• There is a possibility of additional or similar complaints or demand letters being received, which could further complicate the merger process.
• The necessity to issue supplemental disclosures, even if denied as legally required, suggests a perceived deficiency or risk in the original filing that needed to be addressed.

Risks

• One or more closing conditions to the transaction may not be satisfied or waived, on a timely basis or otherwise, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed transaction, or may require conditions, limitations or restrictions in connection with such approvals.
• The required approval by the stockholders of Waters may not be obtained.
• The proposed transaction may not be completed on the terms or in the time frame expected by Waters, BD and SpinCo, or at all.
• Unexpected costs, charges or expenses resulting from the proposed transaction.
• Uncertainty of the expected financial performance of the combined company following completion of the proposed transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the proposed transaction or integrating the businesses of Waters and SpinCo, on the expected timeframe or at all.
• The ability of the combined company to implement its business strategy.
• Difficulties and delays in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• The occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation in connection with the proposed transaction or other litigation, settlements or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification and liability.
• Evolving legal, regulatory and tax regimes.
• Changes in general economic and/or industry specific conditions or any volatility resulting from the imposition of and changing policies around tariffs.
• Actions by third parties, including government agencies.
• The risk that the anticipated tax treatment of the proposed transaction is not obtained.
• The risk of greater than expected difficulty in separating the business of SpinCo from the other businesses of BD.
• Risks related to the disruption of management time from ongoing business operations due to the pendency of the proposed transaction, or other effects of the pendency of the proposed transaction on the relationship of any of the parties to the transaction with their employees, customers, suppliers, or other counterparties.
• The credit ratings of the combined company declines following the proposed acquisition.
• The announcement or the consummation of the proposed acquisition has a negative effect on the market price of the capital stock of Waters and BD or on Waters and BDs operating results.

Future Outlook

The proposed merger between Waters and BD's Biosciences and Diagnostic Solutions business is expected to be a tax-efficient Reverse Morris Trust transaction. Management anticipates strong revenue and cost synergy opportunities, including cross-selling Waters products into research markets, promoting LC-MS in clinical diagnostics, and optimizing logistics, procurement, and related costs. The combined company aims to implement its business strategy and realize these anticipated benefits, although risks related to integration, personnel retention, and market conditions remain.

Management Comments

• Waters believes that the disclosures set forth in the Proxy Statement/Prospectus comply fully with all applicable law, that no further disclosure beyond that already contained in the Proxy Statement/Prospectus is required under applicable law, and believes it has meritorious arguments against the Complaints and the Demand Letters.
• Waters has determined to voluntarily supplement certain disclosures in the Proxy Statement/Prospectus to moot these disclosure claims, and to minimize any risk of delay to the consummation of the Merger or other adverse effects on the transactions, and to avoid the costs, risks and uncertainties inherent in defending such lawsuits, without admitting any culpability, liability or wrongdoing.
• Waters board of directors continues to recommend unanimously that you vote FOR the proposals being considered at the special meeting of Waters stockholders.

Industry Context

This announcement highlights a strategic consolidation within the life sciences and diagnostics industry, where companies like Waters are seeking to expand their market presence and technological capabilities through M&A. The Reverse Morris Trust structure is a common method for tax-efficient divestitures and mergers. The detailed comparable company and precedent transaction analyses reflect the high valuation multiples and active M&A environment in this sector, driven by innovation and demand for advanced analytical and diagnostic solutions. The anticipated synergies suggest a move towards integrated solutions and broader market penetration.

Comparison to Industry Standards

• **Waters Comparable Companies (EV / Adj. EBITDA 25 Multiple / 26 Multiple)**: Thermo Fisher Scientific (17.7x / 16.2x), Danaher Corporation (21.0x / 19.2x), Agilent Technologies, Inc. (18.4x / 16.9x), Revvity, Inc. (16.0x / 14.7x), Avantor, Inc. (11.1x / 10.4x), Qiagen N.V. (14.5x / 13.5x), Bio-Rad Laboratories, Inc. (16.9x / 15.2x), Mettler Toledo (22.5x / 20.9x), Bio-Techne Corporation (19.5x / 17.6x), Bruker Corporation (13.2x / 12.0x). These benchmarks provide context for Waters' valuation in the sector.
• **BDS Business Comparable Companies (EV / Adj. EBITDA 25 Multiple / 26 Multiple)**: Includes the same companies as Waters, plus Waters itself (20.0x / 18.6x), BioMrieux SA (14.0x / 12.7x), Diasorin (13.8x / 12.3x). This broader set helps assess the relative valuation of the BDS Business within its specific sub-segment.
• **Selected Precedent Transactions (Approx. LTM Multiples)**: The filing lists numerous transactions, including Ingersoll Rand's acquisition of ILC Dover (~17.5x LTM Multiple), Danaher's acquisition of Abcam (~32.2x), Waters' acquisition of Wyatt Technology (~27.2x), Thermo Fisher's acquisition of The Binding Site (~36.4x), and Danaher's acquisition of General Electric's Biopharma business (~18.5x). These transactions provide a range of valuation multiples (from ~13.7x to ~36.4x) for M&A activities in related industries, indicating the potential valuation context for the Waters-SpinCo merger.

Corporate Governance

Legal Proceedings

• Two lawsuits have been filed by purported stockholders of Waters in the Supreme Court of the State of New York, New York County: 'Ryan Carroll v. Waters Corporation, et al.' (No. 650159/2026) and 'Joseph Clark v. Waters Corporation, et al.' (No. 650180/2026).
• These lawsuits allege that the Proxy Statement/Prospectus omitted certain purportedly material information that rendered such document incomplete and misleading.
• Waters has also received demand letters from purported stockholders making similar allegations regarding the Proxy Statement/Prospectus.
• Waters believes its disclosures comply fully with all applicable law and has meritorious arguments against the complaints and demand letters, but is providing supplemental disclosures to moot the claims and minimize delay risks.

Stakeholder Impact

• **Shareholders (Waters)**: Will vote on the merger, potentially receiving shares of the combined company. They are directly impacted by the ongoing litigation and the supplemental disclosures, which aim to provide more complete information for their voting decision.
• **Shareholders (BD)**: Will receive SpinCo Common Stock via a pro rata distribution as part of the Reverse Morris Trust transaction.
• **Employees (Waters & SpinCo)**: Potential for integration challenges, changes in corporate culture, and retention issues post-merger. The filing mentions the risk of inability to retain and hire key personnel.
• **Customers & Suppliers**: May experience disruptions or changes in relationships due to the merger and subsequent integration of the businesses.
• **Creditors**: The credit ratings of the combined company could decline following the proposed acquisition, potentially impacting borrowing costs and access to capital.

Next Steps

• Waters stockholders will hold a special meeting on January 27, 2026, to vote on the proposals necessary to complete the Merger.
• The consummation of the Merger, subject to the terms and conditions of the Definitive Agreements, will occur following stockholder approval and satisfaction of other closing conditions.
• Upon completion of the Merger, SpinCo will become a wholly owned subsidiary of Waters, leading to integration activities.

Key Dates

Recommendation

The proposed merger with BD's Biosciences and Diagnostic Solutions business is a significant strategic move for Waters, offering potential for strong synergies and market expansion. The board's unanimous recommendation and the tax-efficient structure are positive indicators. However, the ongoing shareholder litigation alleging disclosure deficiencies introduces a material level of uncertainty and potential for delays, increased legal costs, or even a renegotiation of terms. While Waters is proactively addressing these concerns with supplemental disclosures, the legal overhang warrants a cautious 'hold' position. Investors should monitor the outcome of the shareholder vote and the resolution of the litigation before making further investment decisions, as these factors could significantly impact the deal's completion and the combined entity's near-term performance.

Keywords

Waters Corporation, Becton Dickinson, BD, SpinCo, Merger, Reverse Morris Trust, SEC Filing, 8-K, Proxy Statement, Shareholder Litigation, Biosciences, Diagnostic Solutions, Financial Projections, Corporate Governance, M&A, Stockholder Vote